Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2010 1
2011 2
2013 1
2015 1
2016 4
2017 5
2018 9
2019 13
2020 12
2021 19
2022 16
2023 14
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy.
Nicaise EH, Schmeusser BN, Ali A, Midenberg E, Palacios AR, Hartsoe B, Kearns E, Ambadi S, Patil DH, Joshi SS, Narayan VM, Psutka SP, Nazha B, Brown JT, Ogan K, Bilen MA, Master VA. Nicaise EH, et al. Among authors: joshi ss. Clin Genitourin Cancer. 2024 Feb 16:102056. doi: 10.1016/j.clgc.2024.02.007. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38443295
Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker.
Schmeusser BN, Biermann H, Nicaise EH, Ali AA, Patil DH, Midenberg E, Helman T, Armas-Phan M, Nabavizadeh R, Joshi SS, Narayan VM, Bilen MA, Psutka SP, Ogan K, Master VA. Schmeusser BN, et al. Among authors: joshi ss. Oncologist. 2023 Dec 11;28(12):e1219-e1229. doi: 10.1093/oncolo/oyad218. Oncologist. 2023. PMID: 37540787 Free PMC article.
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702 Free article.
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sanda GE, Shabto JM, Goyal S, Liu Y, Martini DJ, Nazha B, Brown JT, Yantorni LB, Anne Russler G, Caulfield S, Joshi SS, Narayan VM, Kissick H, Ogan K, Master VA, Carthon BC, Kucuk O, Bilen MA. Sanda GE, et al. Among authors: joshi ss. Oncologist. 2023 Dec 11;28(12):1072-1078. doi: 10.1093/oncolo/oyad154. Oncologist. 2023. PMID: 37285524 Free PMC article.
Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus.
Schmeusser BN, Midenberg E, Palacios AR, Ali AA, Patil DH, Higgins M, Nabavizadeh R, Croll B, Williams M, Sheehy J, Zheng B, Narayan VM, Joshi SS, Ogan K, Psutka SP, Bilen MA, Master VA. Schmeusser BN, et al. Among authors: joshi ss. Clin Genitourin Cancer. 2023 Aug;21(4):475-482.e4. doi: 10.1016/j.clgc.2023.04.005. Epub 2023 Apr 19. Clin Genitourin Cancer. 2023. PMID: 37210313
Editorial Commentary.
Donnenfeld SR, Joshi SS. Donnenfeld SR, et al. Among authors: joshi ss. Urol Pract. 2022 May;9(3):228. doi: 10.1097/UPJ.0000000000000295.02. Epub 2022 Feb 7. Urol Pract. 2022. PMID: 37145548 No abstract available.
81 results